Long-term safety study of INZ-701
Treatments studied
Part of Blood & lymphatic, Genetic & congenital, Heart & circulation, Skin clinical trials.
This long-term safety study looks at the drug INZ-701 for people with two rare conditions called ENPP1 and ABCC6 deficiencies. If you already took part in an earlier study of this drug, this trial will monitor you over a longer period to see how safe and well it works over time.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be older than 1 year old.
- You must have finished a previous clinical study with the drug INZ-701 for ENPP1 or ABCC6 deficiency.
- If you could become pregnant or get someone pregnant, you must be willing to use highly effective birth control during the study and for 30 days after your last dose.
- You cannot be pregnant, breastfeeding, or trying to conceive a child.
- You must not have a known allergy or intolerance to INZ-701 or any of its ingredients.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new medicine called JNT-517 for people with phenylketonuria (PKU) over a long period. It aims to see if the drug can help manage PKU safely and effectively.
This study tests a new drug called EPN-701 for calciphylaxis, a serious condition where calcium deposits damage blood vessels and skin, causing painful sores. If you have this condition and are on regular dialysis, this trial may help reduce your pain and heal your wounds.
This trial tests an investigational drug (AG-181) for people with PKU who have a specific genetic change (R408W mutation). It aims to check if the drug is safe and how it works in your body.
This trial tests a new study drug called AZD1613 for adults with a certain type of kidney disease (ADPKD). Researchers want to see if it is safe, how the body handles it, and what the right dose might be.
This study tracks the long-term safety of Palynziq (pegvaliase) in people with PKU as they take the medicine over time. It may help you and other patients understand long-term side effects and whether Palynziq stays safe.
This trial tests the long-term safety and effectiveness of NTQ5082 for people who have already taken part in a previous NTQ5082 study and benefited from it, or who were in the control group and received eculizumab. It aims to see if continued treatment is safe and helpful over a longer period.
Hear when a new Pseudoxanthoma Elasticum trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.